other material
confidence high
sentiment positive
materiality 0.75
Leap Therapeutics reports 19.5-month median OS from DKN-01 combo in gastric cancer; data at ASCO 2023
CYPHERPUNK TECHNOLOGIES INC.
- Median OS 19.5 months, median PFS 11.3 months in first-line GEA patients (n=25), exceeding current benchmarks.
- ORR 73% in mITT population; 86% ORR in PD-L1-low patients; 90% ORR in DKK1-high patients.
- Additional partial response after 22 months of therapy; tumor reductions deepen over time.
- Part C randomized controlled trial enrolling; completion expected late 2023; colorectal data coming.